SPPI Stock Sinks on Trial Update

SPPI short sellers are cheering the sell-0ff

Dec 26, 2019 at 10:28 AM
facebook twitter linkedin

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is one of the biggest losers early on today, down 55.8% at $3.87, after the company's cancer drug poziotinib failed a mid-stage study, with the shares hitting a three-year bottom of $3.61 already as a result. This move could spark bearish analyst attention for the drugmaker, since all five covering brokerage firms came into with "strong buy" recommendations.

Looking at recent options trading, there was a near even split between call buying and put buying. Overall, call buying barely outpaced put buying by a ratio of 1.20 in the past 10 days at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), with peak open interest sitting at the January 2020 5- and 7-strike puts.

Not surprisingly, short interest is also elevated on Spectrum Pharmaceuticals, though it's short-sale restricted today due to the massive move. Based on average daily trading volumes, it'd take roughly eight sessions for SPPI short sellers to cover their bearish bets.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners